RecruitingNot ApplicableNCT06021275

Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars


Sponsor

Alexandria University

Enrollment

40 participants

Start Date

Oct 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Recently, few studies have attempted to test the regenerative effects of human insulin application by microneedling on atrophic scars versus other topical preparations. However, the scars were limited etiologically to acne scars. In addition, a lack of inclusion of a control group instead of comparing topical preparations with insulin was also a limitation to these studies. A control group consisting of microneedling alone would have served as a better comparison in order to determine whether the effects of microneedling are augmented by topical protein-rich preparations.


Eligibility

Min Age: 12 YearsMax Age: 60 Years

Inclusion Criteria3

  • Patients aged 12 to 60 years
  • Atrophic scars (traumatic or surgical)
  • Completely healed scars

Exclusion Criteria6

  • Patients with a tendency or history of hypertrophic or keloidal scars
  • Patients who received treatment for their scar in the past 3 months
  • Diabetic patients or those with a history of Dysglycemia
  • Pregnant, or lactating females
  • Patients with active infection at the site of scar
  • Patients currently receiving isotretinoin treatment or in the past month

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMicroneedling with topical application of regular insulin

Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group

OTHERMicroneedling with topical application of saline

Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group


Locations(1)

Alexandria University, Faculty of Medicine

Alexandria, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06021275


Related Trials